---
title: Literature Support for Targeted Therapy
description: In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.
image: https://blog.fidocure.com/hubfs/Imported_Blog_Media/literature_support_for_targeted_therapy.png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# Literature Support for Targeted Therapy
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp)
In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.
Over 20 peer reviewed publications showcase these points.
Here are a few:
**Hemangiosarcoma (HSA)**
[Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229728)
[Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor](https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5810.2004.00057.x)
**Histiocytic Sarcoma**
[Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib](https://www.ingentaconnect.com/contentone/aalas/cm/2019/00000069/00000001/art00003?crawler=true&mimetype=application/pdf)
[Targeting MEK in a Translational Model of Histiocytic Sarcoma](https://mct.aacrjournals.org/content/molcanther/17/11/2439.full.pdf)
**Thyroid Carcinoma**
[Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018)](https://onlinelibrary.wiley.com/doi/abs/10.1111/vco.12571)
**Transitional Cell Carcinoma (TCC)**
[Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines](https://onlinelibrary.wiley.com/doi/abs/10.1111/vco.12434)
[Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.](http://molpharm.aspetjournals.org/content/96/1/36.abstract)
**Pulmonary Adenocarcinoma**
[Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma](https://www.biorxiv.org/content/biorxiv/early/2019/02/25/528182.full.pdf)
**Solid Tumors**
[Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours∗](https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1476-5829.2011.00275.x)
[Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose](https://link.springer.com/article/10.1186/1746-6148-9-190)
**Lymphoma**
[Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines](https://avmajournals.avma.org/doi/abs/10.2460/ajvr.69.7.938)
[The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033347/)
**Apocrine Gland Anal Sac Adenocarcinoma (AGASACA)**
[Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs](https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvim.15706)
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
### [Why Genetic Testing Matters Before Using Targeted Small Molecule Therapies in Cancer Treatment](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment)
*Lucas Rodrigues, DVM, MS, PhDHead of Veterinary Research at FidoCure*
Precision medicine has revolutionized human oncology by enabling treatments tailored to the unique...
[Dr. Lucas Rodrigues](https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues)
[Read More](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment)
[](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/fidocure-targeted-therapies-early-data-shows-similar-adverse-effects-to-palladia)
### [FidoCure® Targeted Therapies Early Data Shows Similar Adverse Effects to Palladia](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/fidocure-targeted-therapies-early-data-shows-similar-adverse-effects-to-palladia)
To accommodate, we worked hard to move up the release date of our adverse effects data summary. Our data is based on 455 canine patients who enrolled in FidoCure-enabled...
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/fidocure-targeted-therapies-early-data-shows-similar-adverse-effects-to-palladia)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Dr. Gerry Post",
"url" : "https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post"
},
"dateModified" : "2023-04-05T18:56:34.609Z",
"datePublished" : "2020-07-16T04:00:00.000Z",
"headline" : "Literature Support for Targeted Therapy",
"image" : [ "https://blog.fidocure.com/hubfs/Imported_Blog_Media/literature_support_for_targeted_therapy.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```